Breaking News Instant updates and real-time market news.

HZNP

Horizon Pharma

$19.57

0.01 (0.05%)

04:55
12/12/18
12/12
04:55
12/12/18
04:55

Horizon Pharma management to meet with Jefferies

Meeting to be held in San Francisco on December 12 hosted by Jefferies.

  • 12

    Dec

  • 12

    Dec

HZNP Horizon Pharma
$19.57

0.01 (0.05%)

10/23/18
STFL
10/23/18
NO CHANGE
STFL
Buy
Selecta SEL-212 data 'very competitive to Krystexxa mono/combo therapy, says Stifel
Stifel analyst Derek Archila views Selecta Biosciences (SELB) SEL-212 Phase 2 data in chronic severe gout as positive and thinks it represents a "very competitive" emerging profile relative to the incumbent brand, Horizon Pharma's (HZNP) Krystexxa. The analyst comes away positive with the fact SEL-212's projected response rate remains competitive on a modified intent-to-treat basis, SVP-Rapamycin was tolerable out to five months of dosing, and SEL-212's rate of gout flares was lower than Krystexxa alone and Krystexxa+methotrexate early on. Archila remains positive on the stock and believes SEL-212 could offer an improvement to the current standard of care for chronic severe gout. Further, Archila does not believe shares fully reflect the program's commercial potential and reiterates a Buy rating on Selecta's shares.
11/01/18
STFL
11/01/18
NO CHANGE
Target $35
STFL
Buy
Horizon Pharma price target raised to $35 from $25 at Stifel
After hosting a call with a leading oculoplastic surgeon, Stifel analyst Annabel Samimy said she gained further confidence in her view that teprotumumab will have clinical success in Phase 3 and, more importantly, commercial success. Assuming a "high probability of success" of about 85% for teprotumumab, she raised her price target for Horizon Pharma shares to $35 from $25 and keeps a Buy rating on the stock.
11/15/18
MZHO
11/15/18
DOWNGRADE
Target $21
MZHO
Neutral
Horizon Pharma downgraded to Neutral from Buy at Mizuho
Mizuho analyst Irina Koffler downgraded Horizon Pharma to Neutral and lowered her price target for the shares to $21 from $25. After speaking with management about planned investments in teprotumumab pre-launch and the Mirror trial, the analyst reduced her 2019 forecasts for Krystexxa and Actimmune to below consensus. Apart from the "well-telegraphed Krystexxa cliff" in Q1 of 2019, limited Iqvia demand visibility during the first half of next year and already bullish expectations for strong Phase III teprotumumab readout in Q2 warrant increased caution in Horizon shares, Koffler tells investors in a research note. She believes consensus estimates for 2019 are too high and views the stock as fairly valued at $21.
11/15/18
11/15/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Blue Apron (APRN) downgraded to Neutral from Buy at Guggenheim with analyst Michael Graham saying the company's net loss of 71K customers was higher than anticipated even though EBITDA came in higher than expected. 2. Horizon Pharma (HZNP) downgraded to Neutral from Buy at Mizuho with analyst Irina Koffler saying after she spoke with management about planned investments in teprotumumab pre-launch and the Mirror trial, she reduced her 2019 forecasts for Krystexxa and Actimmune to below consensus. 3. Cabot Oil & Gas (COG) downgraded to Hold from Buy at Tudor Pickering. 4. Hawaiian Electric (HE) downgraded to Underperform from Neutral at BofA/Merrill with analyst Julien Dumoulin-Smith citing strong relative share performance on investor activism. 5. PG&E (PCG) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Stephen Byrd saying he sees an "unprecedented" level of uncertainty given that there is currently no liability cap that would be applied to 2018 wildfires. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

MGP

MGM Growth

$32.46

-0.39 (-1.19%)

16:30
11/19/19
11/19
16:30
11/19/19
16:30
Syndicate
MGM Growth 24M share Spot Secondary; price range $31.25-$31.75 »

JPMorgan, Morgan Stanley,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
11/19/19
11/19
16:30
11/19/19
16:30
Options
Preliminary option volume of 19.3M today »

Preliminary option volume…

VAL

Valaris

$3.69

-0.51 (-12.14%)

16:29
11/19/19
11/19
16:29
11/19/19
16:29
Initiation
Valaris initiated  »

Valaris initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$19.29

-0.24 (-1.23%)

16:29
11/19/19
11/19
16:29
11/19/19
16:29
Initiation
TechnipFMC initiated  »

TechnipFMC initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MUX

McEwen Mining

$1.51

-0.015 (-0.98%)

16:28
11/19/19
11/19
16:28
11/19/19
16:28
Syndicate
McEwen Mining files to sell common stock, warrants, no amount given »

Roth Capital Partners and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOR

MorphoSys

$29.02

0.82 (2.91%)

16:28
11/19/19
11/19
16:28
11/19/19
16:28
Initiation
MorphoSys initiated  »

MorphoSys initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

HAL

Halliburton

$19.89

-0.26 (-1.29%)

16:28
11/19/19
11/19
16:28
11/19/19
16:28
Initiation
Halliburton initiated  »

Halliburton initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

HP

Helmerich & Payne

$38.38

-0.46 (-1.18%)

16:28
11/19/19
11/19
16:28
11/19/19
16:28
Initiation
Helmerich & Payne initiated  »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTEN

Patterson-UTI

$8.49

-0.095 (-1.11%)

16:27
11/19/19
11/19
16:27
11/19/19
16:27
Initiation
Patterson-UTI initiated  »

Patterson-UTI initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLB

Schlumberger

$34.31

-0.36 (-1.04%)

16:27
11/19/19
11/19
16:27
11/19/19
16:27
Initiation
Schlumberger initiated  »

Schlumberger initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZYME

Zymeworks

$38.27

0.98 (2.63%)

16:27
11/19/19
11/19
16:27
11/19/19
16:27
Initiation
Zymeworks initiated  »

Zymeworks initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

RIG

Transocean

$4.66

-0.16 (-3.32%)

16:27
11/19/19
11/19
16:27
11/19/19
16:27
Initiation
Transocean initiated  »

Transocean initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKR

Baker Hughes

$22.01

-0.155 (-0.70%)

16:26
11/19/19
11/19
16:26
11/19/19
16:26
Initiation
Baker Hughes initiated  »

Baker Hughes initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YMAB

Y-mAbs Therapeutics

$28.51

-0.03 (-0.11%)

16:26
11/19/19
11/19
16:26
11/19/19
16:26
Initiation
Y-mAbs Therapeutics initiated  »

Y-mAbs Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGP

MGM Growth

$32.46

-0.39 (-1.19%)

16:26
11/19/19
11/19
16:26
11/19/19
16:26
Syndicate
MGM Growth files to sell 24M shares of common stock »

J.P. Morgan, Morgan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESE

Esco Technologies

$86.70

1.93 (2.28%)

16:25
11/19/19
11/19
16:25
11/19/19
16:25
Earnings
Breaking Earnings news story on Esco Technologies »

Esco Technologies sees Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

DAN

Dana

$16.80

0.095 (0.57%)

16:25
11/19/19
11/19
16:25
11/19/19
16:25
Initiation
Dana initiated  »

Oppenheimer starts Dana…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALK

Alaska Air

$70.07

0.1 (0.14%)

16:25
11/19/19
11/19
16:25
11/19/19
16:25
Initiation
Alaska Air initiated  »

Alaska Air initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HA

Hawaiian Holdings

$31.03

0.56 (1.84%)

16:25
11/19/19
11/19
16:25
11/19/19
16:25
Initiation
Hawaiian Holdings initiated  »

Hawaiian Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAVE

Spirit Airlines

$38.85

0.92 (2.43%)

16:24
11/19/19
11/19
16:24
11/19/19
16:24
Initiation
Spirit Airlines initiated  »

Spirit Airlines initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESE

Esco Technologies

$86.70

1.93 (2.28%)

16:24
11/19/19
11/19
16:24
11/19/19
16:24
Earnings
Esco Technologies sees FY20 ex-items EPS $3.20-$3.30, two estimates $3.62 »

Sees FY20 revenue up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

HD

Home Depot

$225.91

-13.07 (-5.47%)

, KSS

Kohl's

$47.01

-11.38 (-19.49%)

16:22
11/19/19
11/19
16:22
11/19/19
16:22
On The Fly
Fly Intel: Wall Street's top stories for Tuesday »

The major averages had a…

HD

Home Depot

$225.91

-13.07 (-5.47%)

KSS

Kohl's

$47.01

-11.38 (-19.49%)

MDCO

The Medicines Co.

$70.17

11.51 (19.62%)

NVS

Novartis

$90.42

0.14 (0.16%)

BRY

Berry Petroleum

$8.90

-2.405 (-21.27%)

MYOV

Myovant Sciences

$13.00

6.98 (115.95%)

TJX

TJX

$60.66

1.12 (1.88%)

M

Macy's

$15.03

-1.85 (-10.96%)

MSFT

Microsoft

$150.35

(0.00%)

WORK

Slack Technologies

$21.17

-1.93 (-8.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

AMRN

Amarin

$22.73

0.1 (0.44%)

16:21
11/19/19
11/19
16:21
11/19/19
16:21
Initiation
Oppenheimer starts Amarin with $7 target on 'rich' valuation, 'stale' M&A thesis »

Oppenheimer analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

MGP

MGM Growth

$32.46

-0.39 (-1.19%)

16:21
11/19/19
11/19
16:21
11/19/19
16:21
Syndicate
MGM Growth offers to sell 24M shares of common stock »

J.P. Morgan, Morgan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
11/19/19
11/19
16:20
11/19/19
16:20
Options
Closing CBOE SPX and VIX Index summary for November 19th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.